Franklin Genomic Advancements ETF (HELX)

Assets	$13.84M
Expense Ratio	0.50%
PE Ratio	27.95
Shares Out	400,000
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a

Volume	263
Open	27.83
Previous Close	27.64
Day's Range	27.83 - 27.89
52-Week Low	23.74
52-Week High	33.69
Beta	1.03
Holdings	66
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: BATS
• Ticker Symbol: HELX
• ETF Provider: Franklin Templeton

Top 10 Holdings

40.39% of assets

Name	Symbol	Weight
Natera, Inc.	NTRA	5.59%
Alnylam Pharmaceuticals, Inc.	ALNY	5.04%
Medpace Holdings, Inc.	MEDP	4.41%
Samsung Biologics Co.,Ltd.	207940	4.16%
Guardant Health, Inc.	GH	4.12%
Insmed Incorporated	INSM	3.60%
Vertex Pharmaceuticals Incorporated	VRTX	3.51%
Us Dollar	n/a	3.43%
Krystal Biotech, Inc.	KRYS	3.34%
Corteva, Inc.	CTVA	3.17%

Performance

HELX had a total return of -10.96% in the past year, including dividends. Since the fund's inception, the average annual return has been 2.79%.